Increasing Ethanol Tolerance and Ethanol Production in an Industrial Fuel Ethanol Saccharomyces cerevisiae Strain

Autor: Camila S. Varize, Augusto Bücker, Lucas D. Lopes, Renata M. Christofoleti-Furlan, Mariane S. Raposo, Luiz C. Basso, Boris U. Stambuk

Publikováno v: Fermentation, Vol 8, Iss 10, p 470 (2022)

The stress imposed by ethanol to Saccharomyces cerevisiae cells are one of the most challenging limiting factors in industrial fuel ethanol production. Consequently, the toxicity and tolerance to high ethanol concentrations has been the subject of ex

Externí odkaz: https://doaj.org/article/89900f21671c4f0ea73cbb994ee4a0f8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Autor: Fässler, Mirjam, Diem, Stefan, Mangana, Joanna, Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Ring, Sandra, Niederer, Rebekka, Del Carmen Gil Cruz, Cristina, Pérez Shibayama, Christian Ivan, Krolik, Michal, Siano, Marco, Joerger, Markus, Recher, Mike, Risch, Lorenz, Güsewell, Sabine, Risch, Martin, Speiser, Daniel E, Ludewig, Burkhard, Levesque, Mitchell P, Dummer, Reinhard, Flatz, Lukas

Publikováno v: Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; Del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Martin; Speiser, Daniel E; Ludewig, Burkhard; Levesque, Mitchell P; ... (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for immunotherapy of cancer, 7(1), p. 50. BioMed Central 10.1186/s40425-019-0523-2
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 50

Background Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. Methods We investigated the ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0383a55b6649492b2f23f1522734b4
https://boris.unibe.ch/174992/1/50.full.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.